Journals / Ulusal Cerrahi Dergisi / 2015 / Cilt: 31 - Sayı: 4

Ratlarda deneysel olarak cerulein ile oluşturulmuş akut pankreatitte everolimusun etkileri

Effects of everolimus on a rat model of cerulein-induced experimental acute pancreatitis

Pages
185–191
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Histo-pathological analyses revealed that everolimus significantly decreased inflammation and perivascular infiltrate in a dose-dependent manner (35% in Group 2, 75% in Group 3; p=0.048).Conclusion: Treatment with two doses of everolimus improved some biochemical and histopathological parameters of experi-mental rat models of cerulein-induced acute pancreatitis and implied the specific inhibition of inflammatory response pathways.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: To analyze the biochemical and histopathological effects of everolimus in an experimental rat model of ce-rulein-induced acute pancreatitis.
📊
Key Findings & Data:The aim of the present study was to determine the effects of everolimus on blood biochemical parameters and tissue histopathology in an experimental rat model of cerulein-induced acute pancreatitis.Material and Methods: In 30 Wistar albino rats (male; 240-260 g), acute pancreatitis was induced by an intraperitoneal injection of cerulein (50 ?g/kg) administered twice in 2 h.
💡
Conclusion & Impact:Histo-pathological analyses revealed that everolimus significantly decreased inflammation and perivascular infiltrate in a dose-dependent manner (35% in Group 2, 75% in Group 3; p=0.048).Conclusion: Treatment with two doses of everolimus improved some biochemical and histopathological parameters of experi-mental rat models of cerulein-induced acute pancreatitis and implied the specific inhibition of inflammatory response pathways.
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: To analyze the biochemical and histopathological effects of everolimus in an experimental rat model of ce-rulein-induced acute pancreatitis. The aim of the present study was to determine the effects of everolimus on blood biochemical parameters and tissue histopathology in an experimental rat model of cerulein-induced acute pancreatitis.Material and Methods: In 30 Wistar albino rats (male; 240-260 g), acute pancreatitis was induced by an intraperitoneal injection of cerulein (50 ?g/kg) administered twice in 2 h. They were equally divided into the following three groups: 0.9% isotonic solution (Group 1; control), everolimus once (Group 2), and everolimus twice (Group 3) by oral gavage after cerulein injection. Thirty hours after the induction of pancreatitis, blood samples were collected by direct intracardiac puncture, rats were sacrificed, and pancreatic tissue samples were obtained. Results: Biochemical analyses of the blood samples showed statistically significant difference in red blood cell count as well as hemoglobin, hematocrit, urea, and alanine transaminase levels among the study groups (p<0.05 in all). Everolimus proved to significantly increase red blood cell count in a dose-independent manner. Hemoglobin and hematocrit levels significantly increased only after treatment with one dose of everolimus. Urea level was significantly different between the Groups 2 and 3; however, no change was observed in both groups when compared with the control. Alanine transaminase level significantly decreased only after treatment with two doses of everolimus. Histo-pathological analyses revealed that everolimus significantly decreased inflammation and perivascular infiltrate in a dose-dependent manner (35% in Group 2, 75% in Group 3; p=0.048).Conclusion: Treatment with two doses of everolimus improved some biochemical and histopathological parameters of experi-mental rat models of cerulein-induced acute pancreatitis and implied the specific inhibition of inflammatory response pathways.

Özet

Amaç: Deneysel rat modelinde cerulein ile indüklenmiş akut pankreatitte everolimusun biyokimyasal ve histopatolojik etkilerini incelemek. Mevcut çalışmanın amacı cerulein ile indüklenmiş akut pankreatitli deneysel rat modelinde eve-rolimusun kan biyokimyasal parametrelerinde ve doku histopatolojisindeki etkilerini belirlemektir.Gereç ve Yöntemler: Çalışmada, 30 adet Wistar-Albino rat (erkek, 240-260 gr) kullanıldı. Ceruleinin (50 ?g/kg) 2 saat arayla intraperitoneal enjeksiyonu ile akut pankreatit oluşturuldu. Ratlar 3 gruba ayrılarak, cerulein enjeksiyonu son-rası gavaj ile serum fizyolojik verilenler Grup 1, bir kez everolimus verilenler Grup 2 ve iki kez everolimus verilenler Grup 3 olarak isimlendirildi. Pankreatit indüksiyonundan otuz saat sonra kan örnekleri direkt intrakardiyak ponksiyon ile alındı, ratlar sakrifiye edildi ve pankreatik doku örnekleri alındı. Bulgular: Kan örneklerinin biyokimyasal analizleri sonrasında gruplar arasında, kırmızı kan hücreleri, hemoglobin, hematokrit, üre ve alanin transaminaz seviyesinde anlamlı farklılık görüldü (p<0,05). Everolimus doz bağımsız olarak kırmızı kan hücrelerinin seviyesinde anlamlı yükselişe neden oldu. Hemoglobin ve hematokrit seviyeleri ise tek doz everolimus sonrası artış gösterdi. Üre seviyesindeki değişim Grup 2 ve 3 arasında anlamlıyken, kontrol grubuna göre değişim gözlemlenmedi. Alanin transaminaz seviyesi sadece iki doz everolimus sonrası anlamlı bir azalma gösterdi. Histopatojik analizler sonrasında everolimusla doz bağımlı olarak enflamasyon ve perivasküler infiltrasyonda anlamlı azalma olduğu görüldü (Grup 2 %35, Grup 3 %75; p=0,048)Sonuç: Çift doz everolimus tedavisi, cerulein ile indüklenmiş akut pankreatitin oluşturulduğu deneysel rat modelinde histopatolojik ve biyokimyasal parametrelerde değişimler sağlamakta ve bu da inflamatuvar cevap yolaklarının inhi-bisyonunu işaret etmektedir.

🔖

Cite This Article

ÖZKARDEŞ, A. B., BOZKURT, B., DUMLU, E. G., TOKAÇ, M., YAZGAN, A. K., ERGİN, M., EREL, Ö., KILIÇ, M. (2015). Ratlarda deneysel olarak cerulein ile oluşturulmuş akut pankreatitte everolimusun etkileri. Ulusal Cerrahi Dergisi, Cilt: 31 - Sayı: 4, 185–191. https://ajindex.com/articles/325370

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (3)

  1. Bulut NE, Özkan E, Ekinci O, Dulundu E, Topaloğlu Ü, Şehirli AÖ, et al. Beneficial effects of alpha lipoic acid on cerulein-induced experimental acute pancreatitis in rats. Ulus Travma Acil Cerrahi Derg 2011; 17: 383-389. [CrossRef] Hoque R, Malik AF, Gorelick F, Mehal WZ. Sterile inflammatory re- sponse in acute pancreatitis. Pancreas 2012; 41: 353-357. [CrossRef] Kilic E, Amanvermez R, Kefeli M, Polat C, Gunay M. Protective ef- fects of etanercept and methylprednisolone on pancreatic dam- age in cerulein-induced acute pancreatitis. Saudi Med J 2010; 31: 394-399.
  2. Kingsnorth A, O'Reilly D. Acute pancreatitis. BMJ 2006; 332: 1072- 1076. [CrossRef] Kota SK, Krishna SVS, Lakhtakia S, Modi KD. Metabolic pancre- atitis: Ethiopathogenesis and management. Indian J Endocrinol Metab 2013; 17: 799-805. [CrossRef] Bang UC, Semb S, Nojgaard C, Bendtsen F. Pharmocological ap- proach to acute pancreatitis. World J Gastroenterol 2008; 14: 2968-2976. [CrossRef] Easler JJ, Mounzer R, Papachristou GI. Pharmacological therapy for acute pancreatitis: where are we now? where are we going? Minerva Gastroenterol Dietol 2012; 58: 365-376.
  3. Raraty MG, Connor S, Criddle DN, Sutton R, Neoptolemos JP. Acute pancreatitis and organ failure: pathophysiology, natural history, and management strategies. Curr Gastroenterol Rep 2004; 6: 99-103. [CrossRef] Schepers NJ, Besselink MG, van Santvoort HC, Bakker OJ, Bruno MJ; Dutch Pancreatitis Study Group. Early management of acute pancre- atitis. Best Pract Res Clin Gastroenterol 2013; 27: 727-743. [CrossRef] Gabardi S, Baroletti SA. Everolimus: a proliferation signal inhibitor with clinical applications in organ transplantation, oncology, and cardiology. Pharmacotherapy 2010; 30: 1044-1056. [CrossRef] Garnock-Jones KP, Keating GM. Everolimus. Drugs 2009; 69: 2115- 2124. [CrossRef] Hougton PJ. Everolimus. Clin Cancer Res 2010; 16: 1368-1372. [CrossRef] Nashan B. Review of the proliferation inhibitor everolimus. Drug Evaluation 2002; 11: 1845-1857. [CrossRef] Lebwohl D, Anak O, Sahmoud T, Klimovsky J, Elmroth I, Haas T, et al. Development of everolimus, a novel oral mTOR inhibitor, across a spectrum of diseases. Ann N Y Acad Sci 2013; 1291: 14- 32. [CrossRef] Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E. Evero- limus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011;364:514-523. [CrossRef] Erel O. A novel automated method to measure total antioxidant response against potent free radical reactions. Clin Biochem 2004; 37: